Lack of metabolic effects of a triphasic formulation containing norethindrone in normal women studied prospectively.
The glucose and insulin responses to oral glucose tolerance tests and lipid values in normal women taking a triphasic pill containing norethindrone (Ortho 7/7/7) were performed. After three months, no significant changes in these metabolic indices were found. These results confirm and expand the knowledge regarding the metabolic safety of norethindrone-containing triphasic formulations.
Toth
E L
EL
Department of Medicine, University of Alberta, Edmonton, Canada.
Ryan
E A
EA
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D009640:Norethindrone / Q000008:administration & dosage / Q000494:pharmacology*; D011446:Prospective Studies; D012016:Reference Values
D001786:Blood Glucose; D003278:Contraceptives, Oral, Hormonal; D007328:Insulin; D008055:Lipids; D004997:Ethinyl Estradiol; D009640:Norethindrone